Prescribing information

 

 

SANDOSTATIN® LAR® is indicated for the treatment of:

  • Patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours (e.g. carcinoid tumours with features of the carcinoid syndrome) or patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.1
  • Patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.1

 

Reference

  1. SANDOSTATIN® LAR® Summary of Product Characteristics. December 2020.
Rate this content: 
No votes yet
UK | May 2021 | 104730
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com